326 related articles for article (PubMed ID: 11059028)
1. [Swiss registry for patients with cystic fibrosis: design, programming, implementation and first examples of use].
Schöni-Affolter F; Oswald P; Wandt-Baumann C; Kriemler S; Schöni MH
Schweiz Med Wochenschr; 2000 Sep; 130(39):1373-81. PubMed ID: 11059028
[TBL] [Abstract][Full Text] [Related]
2. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis.
Hodson ME; McKenzie S; Harms HK; Koch C; Mastella G; Navarro J; Strandvik B;
Pediatr Pulmonol; 2003 Nov; 36(5):427-32. PubMed ID: 14520726
[TBL] [Abstract][Full Text] [Related]
3. Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry.
Strobl J; Enzer I; Bagust A; Haycox A; Smyth R; Ashby D; Walley T
Pharmacoepidemiol Drug Saf; 2003 Sep; 12(6):467-73. PubMed ID: 14513660
[TBL] [Abstract][Full Text] [Related]
4. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.
McKenzie SG; Chowdhury S; Strandvik B; Hodson ME;
Pediatr Pulmonol; 2007 Oct; 42(10):928-37. PubMed ID: 17726701
[TBL] [Abstract][Full Text] [Related]
5. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
6. Dornase alpha in the management of a mechanically ventilated infant with cystic fibrosis.
Kling S; Gie RP; Riphagen S
Pediatr Pulmonol; 1997 Aug; 24(2):124-5. PubMed ID: 9292906
[No Abstract] [Full Text] [Related]
7. Dornase alfa: a new option in the management of cystic fibrosis.
Witt DM; Anderson L
Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
[TBL] [Abstract][Full Text] [Related]
8. [Current therapeutic agents: dornase alfa].
Baran D; Sternon J
Rev Med Brux; 1997 Feb; 18(1):37-40. PubMed ID: 9132917
[TBL] [Abstract][Full Text] [Related]
9. [International registry on mucoviscidosis: comparison of the French data with the European data for 1995].
Delaisi B; Grosskopf C; Reignault E; Goehrs JM; Navarro J
Arch Pediatr; 1998 Apr; 5(4):384-8. PubMed ID: 9759157
[TBL] [Abstract][Full Text] [Related]
10. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.
Rozov T; de Oliveira VZ; Santana MA; Adde FV; Mendes RH; Paschoal IA; Caldeira Reis FJ; Higa LY; Toledo AC; Pahl M;
Pediatr Pulmonol; 2010 Sep; 45(9):874-82. PubMed ID: 20583292
[TBL] [Abstract][Full Text] [Related]
11. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of cystic fibrosis.
Hopkins S
Nurs Times; 1995 Sep 27-Oct 3; 91(39):40-1. PubMed ID: 7567556
[TBL] [Abstract][Full Text] [Related]
13. [New pharmacological approaches: rhDNase].
Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
[TBL] [Abstract][Full Text] [Related]
14. What is the cystic fibrosis clinician supposed to do with human recombinant dornase alfa?
Coates AL
J Pediatr; 2001 Dec; 139(6):768-70. PubMed ID: 11743499
[No Abstract] [Full Text] [Related]
15. Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis.
Padman R; Werk LN; Ramirez-Garnica G; Ye G; Nathanson I
J Cyst Fibros; 2008 Sep; 7(5):385-90. PubMed ID: 18342580
[TBL] [Abstract][Full Text] [Related]
16. [2 significant stages in the management of mucoviscidosis: the French experience with dornase alfa (Pulmozyme) and the impact in international registries].
Brémont F; Navarro J
Arch Pediatr; 1998 Apr; 5(4):367-70. PubMed ID: 9759154
[No Abstract] [Full Text] [Related]
17. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
18. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha.
Ratjen F; Paul K; van Koningsbruggen S; Breitenstein S; Rietschel E; Nikolaizik W
Pediatr Pulmonol; 2005 Jan; 39(1):1-4. PubMed ID: 15532079
[TBL] [Abstract][Full Text] [Related]
19. Aerosolized deoxyribonuclease for cystic fibrosis.
Med Lett Drugs Ther; 1994 Apr; 36(920):34-5. PubMed ID: 8145672
[No Abstract] [Full Text] [Related]
20. Pulmozyme--Dornase alfa.
Gutteridge C; Kuhn RJ
Pediatr Nurs; 1994; 20(3):278-9. PubMed ID: 8008477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
